Resverlogix Announces One-Year Extension of Debenture

• The most recent release (May 11, 2026) announces a one-year extension on a US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
• Maturity date extended to May 13, 2027.
• Annual interest rate increased from 18% to 20%, effective May 14, 2026.
• Historical context reveals a Management Cease Trade Order (MCTO) issued April 2, 2026, due to missed FY2025 filing deadlines (March 31, 2026).
• A prior financing event on February 18, 2026, involved a $2.8 million shares-for-interest private placement with an immediate family member of the Chairman/CEO to settle accrued interest owed to Zenith Capital Corp.

• The debt extension prevents immediate default on US$6.0 million in secured obligations, providing critical liquidity runway for another year.
• However, the increase in interest rate from 18% to 20% significantly increases the cost of capital and cash burn rate.
• The regulatory overhang remains unresolved; the MCTO was issued April 2 with an expected filing completion date of April 10, yet no confirmation of filing resolution is present in the May 11 release.
• This news is consistent with previous distress signals (shares-for-interest financing) rather than a fundamental business turnaround.
• The extension stabilizes solvency but does not address the compliance risks or operational growth catalysts required for valuation expansion.

• Resverlogix Corp operates in the biotechnology and pharmaceutical sector, focusing on health supplements or drug candidates (implied by name and Hepalink partnership).
• The company has faced significant operational challenges regarding financial reporting compliance as evidenced by the MCTO.
• No specific details on product pipelines are provided in the current news set, limiting assessment of commercial viability beyond debt servicing capability.